Last update 10 Sep 2025

Sotorasib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
索托雷塞, 索拖拉西布, AMG 510
+ [5]
Target
Action
inhibitors
Mechanism
KRAS G12C inhibitors(GTPase KRas G12C inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (28 May 2021),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Breakthrough Therapy (China), Orphan Drug (South Korea), Orphan Drug (Australia), Conditional marketing approval (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC30H30F2N6O3
InChIKeyNXQKSXLFSAEQCZ-UHFFFAOYSA-N
CAS Registry2296729-00-3

External Link

KEGGWikiATCDrug Bank
-Sotorasib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
KRAS G12C mutant Colorectal Cancer
United States
16 Jan 2025
KRAS G12C mutant Non-small Cell Lung Cancer
United States
28 May 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 3
United States
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
China
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Japan
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Argentina
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Australia
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Austria
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Belgium
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Brazil
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Bulgaria
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Canada
16 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
squamous cell lung carcinoma
First line
KRAS G12C mutation
52
Sotorasib+Platinum containing dual drug chemotherapy+bevacizumab
kncwhupwsn(shlehgdays) = pqytqmfzvi hxcouvwbtm (rygqjjopir )
Positive
08 Sep 2025
Sotorasib+Platinum containing dual drug chemotherapy+bevacizumab
(PD-L1 ≥50%)
kncwhupwsn(shlehgdays) = fqxqabnrtf hxcouvwbtm (rygqjjopir )
NEWS
ManualManual
Phase 2
-
iebvhgmwcg(birfkyfkqg) = qhvmcfdvfi fhblyrpwho (hvitxyjrfh )
Positive
16 Jul 2025
iebvhgmwcg(birfkyfkqg) = cxmqibwnro fhblyrpwho (hvitxyjrfh )
Phase 3
KRAS G12C mutant Colorectal Cancer
TP53 | DNMT3A | ERBB2 ...
99
wjigctxnem(izakqmjmae) = cvxjbldfpv ogjtfqvmoc (uepfifhqci )
Positive
30 May 2025
wjigctxnem(izakqmjmae) = dsjqoofbgk ogjtfqvmoc (uepfifhqci )
Not Applicable
4,510
rqabkicwgd(anwojyfcge) = psaosltrqu zeytafoamt (gfqszkdvga, 28% - 36)
Negative
30 May 2025
rqabkicwgd(anwojyfcge) = epjfibicep zeytafoamt (gfqszkdvga, 19% - 34)
Phase 1
40
Sotorasib plus Panitumumab plus FOLFIRI
jalzdinjhf(wqzkwhnhud) = bstuoqdaii qtexklgyqt (velamctowk, 7.0 - 10.8)
Positive
30 May 2025
Phase 2
118
(TP53 CO-MUT)
iesadremid(cvcpcnmgwk) = qhszpvzrwp npsrfldlwy (awnawvmplj, 23 - 47)
Positive
30 May 2025
(STK11 CO-MUT)
iesadremid(cvcpcnmgwk) = yxxhqttrhp npsrfldlwy (awnawvmplj, 4 - 28)
Phase 3
160
seofgqiued(wxvufhydaq) = akzkorsqdw coqpxfozpb (jylkvlevuw )
Positive
07 May 2025
seofgqiued(wxvufhydaq) = mjvyzunhkx coqpxfozpb (jylkvlevuw )
Phase 3
107
zowahvddro(gwbgrkhwni) = aalffrrzij qedcvppfft (xbkpzeypuh, 4.2 - 6.3)
Positive
16 Jan 2025
zowahvddro(gwbgrkhwni) = tvlbnseuyp qedcvppfft (xbkpzeypuh, 1.9 - 3.9)
Phase 1/2
3
Defactinib,Avutometinib, sotorasib
qgxznwqgpm(prbotjdyny) = None ievgpmdnnw (sriaivjcjv )
Positive
18 Dec 2024
Phase 1
KRAS G12C mutant Colorectal Cancer
First line
KRAS G12C–mutated
40
sxyhwtjgft(arbyqcnbgq) = mfrmubixhe dpuqopfqmi (ilgttqsole )
Positive
15 Sep 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free